Skip to main content
. 2022 Sep 20;23(19):11023. doi: 10.3390/ijms231911023

Figure 1.

Figure 1

Strategies to target p53 aggregation as anticancer candidates. (A) Thiol alkylating agents targeting mutp53 cysteines. (B) Designed peptides that bind in a complementary way to regions of p53 with a greater propensity to aggregate. (C) Miscellaneous compounds with anti-protein aggregation properties previously tested in neurodegenerative diseases. (D) Compounds with metallochaperone- or molecular-chaperone-based mechanisms.